Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: A randomized controlled trial

JAMA

Volumn 292, Issue 23, 2004, Pages 2839-2848

  Carrat, Fabrice ^a   Bani Sadr, Firouzé ^a   Pol, Stanislas ^a   Rosenthal, Eric ^b   Lunel Fabiani, Françoise ^c   Benzekri, Asmae ^d   Morand, Patrice ^d   Goujard, Cécile ^e   Pialoux, Gilles ^f   Piroth, Lionel ^g   Salmon Céron, Dominique ^h   Degott, Claude ^d   Cacoub, Patrice ^f   Perronne, Christian ⁱ  

^a INSERM   (France)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^c ANGERS UNIVERSITY HOSPITAL   (France)

^d GRENOBLE UNIVERSITY HOSPITAL   (France)

^e UNIVERSITÉ PARIS SACLAY   (France)

^f SORBONNE UNIVERSITÉ   (France)

^g DIJON UNIVERSITY HOSPITAL   (France)

^h UNIVERSITÉ PARIS DESCARTES   (France)

ⁱ RAYMOND POINCARÉ HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ACUTE PANCREATITIS; ADULT; APPETITE DISORDER; ARTICLE; BODY WEIGHT DISORDER; BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEATH; DEPRESSION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GENOTYPE; HEPATITIS C; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; INJECTION PAIN; INSOMNIA; IRRITABILITY; LACTIC ACIDOSIS; LIVER FAILURE; LIVER FIBROSIS; LIVER HISTOLOGY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MITOCHONDRIAL TOXICITY; MULTICENTER STUDY; NEUTROPENIA; PANCREATITIS; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; THROMBOCYTOPENIA; THRUSH; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 10344230440     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.292.23.2839     Document Type: Article

References (38)

1. Lauer G, Walker B. Hepatitis C virus infection. N Engl J Med. 2001;345:41-52.
2. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341: 556-562.
3. Rockstroh JK. Management of hepatitis B and C in HIV Co-infected patients. J Acquir Immune Defic Syndr. 2003;34(suppl 1):S59-S65.
4. Darby SC, Ewart DW, Giangrande PL, et al; UK Haemophilia Centre Directors' Organisation. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. Lancet. 1997;350:1425-1431.
5. Soto B, Sanchez-Quijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol. 1997;26:1-5.
6. Rosenthal E, Poiree M, Pradier C, et al. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS. 2003;17:1803-1809.
7. Cacoub P, Geffray L, Rosenthal E, Perronne C, Veyssier P, Raguin C. Mortality among human immunodeficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French Departments of Internal Medicine/Infectious Diseases, in 1995 and 1997. Clin Infect Dis. 2001;32:1207-1214.
8. Clue P, Fang JW, Rouzier-Panis R, et al. Hepatitis C Intervention Therapy Group. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther. 2000;68:556-567.
9. Bailon P, Palleroni A, Schaffer CA, et al. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem. 2001;12:195-202.
10. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.
11. Manns MP, McHutchison JC, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001; 358:958-965.
12. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346-355.
13. Salmon-Céron D, Lassalle R, Pruvost A, et al. Interferon-ribavirin in association with stavudine has no impact on plasma human immunodeficiency virus (HIV) type 1 level in patients coinfected with HIV and hepatitis C virus: A CORIST-ANRS HC1 trial. Clin Infect Dis. 2003;36:1295-1304.
14. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438-450.
15. Chung RT, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin vs interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351:451-459.
16. Perez-Olmeda M, Nunez M, Romero M, et al. Pegylated IFN-alpha 2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS. 2003;17:1023-1028.
17. Ballesteros AL, Franco S, Fuster D, et al. Early HCV dynamics on Peg-interferon and ribavirin in HIV/ HCV co-infection: indications for the investigation of new treatment approaches. AIDS. 2004;18:59-66.
18. Moreno L, Quereda C, Moreno A, et al. Pegylated Interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. AIDS. 2004;18:67-73.
19. Laguno M, Murillas J, Blanco JL, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS. 2004;18:F27-F36.
20. Bedossa P, Poynard T; The METAVIR Cooperative Study Group. An algorithm for the grading of activity in chronic hepatitis C. Hepatology. 1996;24:289-293.
21. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696-699.
22. Fontaine H, Nalpas B, Poulet B, et al. Hepatitis activity index is a key factor in determining the natural history of chronic hepatitis C. Hum Pathol. 2001;32: 904-909.
23. Molina JM, Ferchal F, Rancinan C, et al. Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients. J Infect Dis. 2000;182:599-602.
24. Zhang J, Yu KF. What's the relative risk? a method of correcting the odds ratio in cohort studies of common outcomes. JAMA. 1998;280:1690-1691.
25. Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology. 2003;37:443-451.
26. Brau N, Bini EJ, Shahidi A, et al. Prevalence of hepatitis C and reinfection with HIV among United States veterans in the New York City metropolitan area. Am J Gastroenterol. 2002;97:2071-2078.
27. Soriano V, Puoti M, Sulkowski M, et al. Care of patients with hepatitis C and HIV co-infection. AIDS. 2004;18:1-12.
28. McHutchison JC, Gordon SC, Schiff ER, et al; Hepatitis Interventional Therapy Group. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. 1998;339: 1485-1492.
29. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000;343:1666-1672.
30. Myers RP, Benhamou Y, Bochet M, Thibault V, Mehri D, Poynard T. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus co-infected non-responders and relapsers to IFN-based therapy. AIDS. 2004;18:75-79.
31. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000;283:74-80.
32. Vento S, Gofano T, Renzini C, Casali F, Ferraro T, Concia E. Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral combination therapy. AIDS. 1998;12:116-117.
33. John M, Flexman J, French MA. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease? AIDS. 1998;12:2289-2293.
34. Becquemont L,Chazouilleres O, Serfaty L, et al. Effect of interferon alpha-ribavirin bitherapy on cytochrome P450 1A2 and 2D6 and N-acetyltransferase-2 activities in patients with chronic active hepaitis C. Clin Pharmacol Ther. 2002;71:488-495.
35. Lafeuillade A, Hittinger C, Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet. 2001;357:280-281.
36. Salmon-Ceron D, Chauvelot-Moachon L, Abad S, Silbermann B, Sogni P. Mitochondrial toxic effects and ribavirin. Lancet. 2001;357:1803-1804.
37. Summary of safety-related drug labeling changes approved by FDA center for drug evaluation and research (CDER) September 2002 Web page. Available at: http://www.fda.gov/medwatch/SAFETY/2002/sep02.htmfvidex. Accessed October 12, 2004.
38. Mauss S, Valenti W, DePamphilis J, et al. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. AIDS. 2004;18:F21-F25.